** Shares of drugmaker Insmed INSM.O rise 24.9% to $88.28 premarket
** Co says its treprostinil palmitil inhalation powder (TPIP) met the main goal in a mid-stage trial by reducing blood flow resistance in the lungs by 35% when compared to placebo
** The drug was tested in patients with Pulmonary Arterial Hypertension (PAH), a rare disease caused by a constriction of arteries in the lungs, leading to high blood pressure
** Co says the treatment is administered once-daily in a capsule-based inhalation device
** INSM says it plans to initiate a late-stage trial for the drug in early 2026
** Up to last close, stock up 2.4% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。